Novoteris, LLC   Report issue

For profit Phase 2
Founded: Garden Grove CA United States (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2017
NCT02498535
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Novoteris, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

nitric oxide (inomax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Infections (Phase 2)

Mycobacterium Infections (Phase 2)

Mycobacterium Infections, Nontuberculous (Phase 2)

Pneumonia (Phase 2)

Respiratory Tract Infections (Phase 2)

Severe Acute Respiratory Syndrome (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1